Aerie Pharmaceuticals focuses on discovering, developing and commercializing therapies for the treatment of open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye. Rhopressa®, Co.'s first U.S. Food and Drug Administration (FDA)-approved product, reduces intraocular pressure (IOP) through Aerie-owned Rho kinase inhibition. Co.'s second FDA-approved product, once-daily Rocklatan®, a fixed-dose combination of Rhopressa® and latanoprost, reduces IOP through the same mechanism of action (MOA) as Rhopressa® and through a second MOA, utilizing the ability of latanoprost to increase the outflow of aqueous humor through the uveoscleral pathway, the eye's secondary drain. We show 32 historical shares outstanding datapoints in our coverage of AERI's shares outstanding history.
Understanding the changing numbers of AERI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AERI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AERI by allowing them to research AERI shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
